Celldex Therapeutics, Inc. cotiza a 28.42 USD y tiene una capitalización bursátil de $2.2B. En los últimos 12 meses ha facturado $158000 con un margen de flujo de caja libre del -13829.1%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which avai…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.94 | $-1.18 | $-1.22 |
| Estimado | $-1.01 | $-1.06 | $-1.13 | $-1.00 |
| Sorpresa | — | +11.3% | -4.4% | -22.0% |
| Métrica | CLDX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 87.1% | 57.0% | +30.0% |
| Operating Margin | -18599.8% | -38.6% | -18561.2% |
| Net Margin | -16748.0% | -33.6% | -16714.5% |
| FCF Margin | -13829.1% | -13.9% | -13815.2% |
| ROE | -49.1% | -40.4% | -8.7% |
| ROA | -44.4% | -32.0% | -12.4% |
| Current Ratio | 10.49 | 2.84 | +7.65 |
| Debt / Equity | — | 0.28 | — |